[go: up one dir, main page]

WO2000040269A3 - Pharmaceutical compositions for treatment of diseased tissues - Google Patents

Pharmaceutical compositions for treatment of diseased tissues Download PDF

Info

Publication number
WO2000040269A3
WO2000040269A3 PCT/US2000/000191 US0000191W WO0040269A3 WO 2000040269 A3 WO2000040269 A3 WO 2000040269A3 US 0000191 W US0000191 W US 0000191W WO 0040269 A3 WO0040269 A3 WO 0040269A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunostimulant
treatment
cytotoxic
composition
diseased cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/000191
Other languages
French (fr)
Other versions
WO2000040269A2 (en
Inventor
Clarence C Lee
Feng-Min Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEE FENG MIN
Original Assignee
LEE FENG MIN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEE FENG MIN filed Critical LEE FENG MIN
Priority to AU34694/00A priority Critical patent/AU3469400A/en
Publication of WO2000040269A2 publication Critical patent/WO2000040269A2/en
Publication of WO2000040269A3 publication Critical patent/WO2000040269A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method to treat diseased tissue is provided where a cytotoxic compound is administered to a patient in need of treatment in combination with an immunostimulant. Diseased cells and/or infectious microbes/viruses are killed by the cytotoxic compound in the presence of the immunostimulant. The cell components including cellular contents and cell membrane fragments are presented by the immunostimulant to the host animal as antigens to stimulate the immune responses toward other diseased cells of the same type(s), that either remain in the vicinity or reside in distant tissues or organs. The cytotoxic molecule and immunostimulant are preferably applied locally at high concentrations, either sequentially or, preferably, simultaneously. For example, the composition can be administered directly to a target cancer. The composition can be prepared in various forms, such as a paste, a time release molded solid shape, a solution, a mixture with emulsifier, etc. Alternatively, the cytotoxic molecule and immunostimulant are applied in sequence.
PCT/US2000/000191 1999-01-05 2000-01-05 Pharmaceutical compositions for treatment of diseased tissues Ceased WO2000040269A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU34694/00A AU3469400A (en) 1999-01-05 2000-01-05 Pharmaceutical compositions for treatment of diseased tissues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11490699P 1999-01-05 1999-01-05
US60/114,906 1999-01-05

Publications (2)

Publication Number Publication Date
WO2000040269A2 WO2000040269A2 (en) 2000-07-13
WO2000040269A3 true WO2000040269A3 (en) 2000-11-30

Family

ID=22358161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/000191 Ceased WO2000040269A2 (en) 1999-01-05 2000-01-05 Pharmaceutical compositions for treatment of diseased tissues

Country Status (2)

Country Link
AU (1) AU3469400A (en)
WO (1) WO2000040269A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US8461123B2 (en) 2005-09-29 2013-06-11 Astex Pharmaceuticals, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DE19957342A1 (en) * 1999-11-29 2001-05-31 Gruenenthal Gmbh Treatment of interleukin (IL)-12 mediated illnesses comprises simultaneous administration of thalidomide or analogue and antiinflammatory cytokine
WO2002069929A1 (en) * 2001-03-06 2002-09-12 Udo Dunzendorfer Trifunctional systems for chronic illnesses
US20020128258A1 (en) * 2001-03-09 2002-09-12 Jean-Pierre Robin Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
WO2004005472A2 (en) * 2002-07-02 2004-01-15 Southern Research Institute Inhibitors of ftsz and uses thereof
KR20200083657A (en) * 2002-12-09 2020-07-08 아브락시스 바이오사이언스, 엘엘씨 Compositions and methods of delivery of pharmacological agents
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007100382A2 (en) 2005-10-27 2007-09-07 Bernstein Lawrence R Orally administrable gallium compositions and method of use
WO2008058210A2 (en) 2006-11-09 2008-05-15 Bernstein Lawrence R Local administration of gallium compositions to treat pain
KR100923884B1 (en) 2007-12-11 2009-10-28 주식회사 알앤엘바이오 Method for preparing alder bark or stem extract with high anti-influenza virus activity
CN102070481A (en) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 Medicine tromantadine with adamantane structure, anti-tumor application of derivates and analogs thereof having new indications
LT2750768T (en) 2011-08-30 2019-02-11 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
RU2712635C1 (en) * 2014-02-05 2020-01-30 Репонекс Фармасьютикалз А/С Compositions for promoting healing of skin ulcers and wounds
US9592188B2 (en) 2014-05-22 2017-03-14 Yansong Liu Method of treating or reducing the severity of dermatological conditions
SI3049430T1 (en) 2014-07-16 2019-06-28 Depofarma S.P.A. Parietal fraction of propionibacterium granulosum having immunomodulating action
EP3848047A1 (en) 2014-07-24 2021-07-14 Reponex Pharmaceuticals APS Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
JP6713148B2 (en) 2014-08-07 2020-06-24 レポネックス・ファーマシューティカルズ・エー／エス Composition for the treatment of peritonitis
CN108024535A (en) 2015-07-02 2018-05-11 大塚制药株式会社 Freeze-drying medicinal composition
RU2020108580A (en) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. MEDICINAL COMPOUNDS AND METHODS OF ITS PURIFICATION
NL2031966B1 (en) * 2022-05-23 2023-11-28 Pleco Therapeutics B V Chelating agents for use in cancer therapy
CN115919830B (en) * 2022-11-29 2025-09-26 中国农业大学 Application of butylparaben in enhancing the antibacterial activity of polymyxins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000832A1 (en) * 1986-07-30 1988-02-11 Immunex Corporation Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
US5476659A (en) * 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) * 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
WO1988000832A1 (en) * 1986-07-30 1988-02-11 Immunex Corporation Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DURIE B. G. M., ET AL.: "High risk thyroid cancer prolonged survival with early multi modality therapy", CANCER CLIN. TRIALS, vol. 4, no. 1, 1981, pages 67 - 74, XP002146549 *
NISHIDA T., ET AL.: "Therapeutic synergism in combination therapy of cis-diamminedichloroplatinum and a bacterial pyrogen on a transplantable ovarian cancer", RECENT ADV. CHEMOTHER.,PROC. INT. CONGR. CHEMOTHER., 14TH, vol. anticancer sect.1, 1985, pages 446 - 447, XP000918402 *
ONYEJI, CYPRIAN O., ET AL.: "Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage coloony-stimulating factor against intromacrophage Mycobacterium avium-Mycobacterium intracellulare", J. INFECT. DIS., vol. 172, no. 3, 1995, pages 810 - 816, XP000918322 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US9308180B2 (en) 2005-08-31 2016-04-12 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US8461123B2 (en) 2005-09-29 2013-06-11 Astex Pharmaceuticals, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein

Also Published As

Publication number Publication date
AU3469400A (en) 2000-07-24
WO2000040269A2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
WO2000040269A3 (en) Pharmaceutical compositions for treatment of diseased tissues
IL133253A0 (en) Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
JP6047207B2 (en) Method and material for forming site-activated complex of biomolecule
WO2005000245A3 (en) Compositions and methods for increasing telomerase activity
DE69030880D1 (en) Composition for stimulating the immune system
AU7285398A (en) Products in the treatment of cancer
WO2006040076A2 (en) Vaccination adjuvants pam3cys, poly(i:c), imiquimod, loxoribine, r-848 and cpg-dna together with mhc i or mhc ii epitopes
AU8180001A (en) Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells
CN101020715B (en) Process of extracting and preparing deer nerve growth factor (DEER NGF)
WO2006068759A3 (en) Liposomes containing phytochemical agents and methods for making and using same
AU5643299A (en) Humic acid and its use in the treatment of various conditions
DE60111637D1 (en) BIOMATERIAL IN THE FORM OF MICROPARTICLES OF HYALURONIC SUCTION FOR MEDICAL USE
US6964783B1 (en) Non-solid composition for local application
Wang et al. Co-encapsulated Ce6+ CpG and biopeptide-modified liposomes for enhanced transdermal photo-immunotherapy of superficial tumors
US20220362400A1 (en) Pivoting electrodynamic composition and medicament
RU2368391C1 (en) Method of getting complex immuno stimulating substance for improvement of autarcesis of animal organism
CN103816110A (en) Preparation method of drug transdermal absorbent promoting fracture healing
RU2228763C1 (en) Method for treating the cases of purulent wounds
WO2002080981A3 (en) Polynucleotide binding complexes comprising sterols and saponins
RU2070411C1 (en) Antiviral medicinal preparation
RU2364414C1 (en) Method of correction of post-stress myocardial dysfunction
EP0753309A2 (en) Preparation of lactoferrin (or analogous proteins) and desferrioxamine methanesulfonate (or other metal ion chelators) for the therapy of viral infectious diseases
Barnes et al. Hormone Influence on the Thiol Content of Hevea brasiliensis Latex
WO2001026680A3 (en) Activation of antigen-specific t cells by virus/antigen-treated dendritic cells
DE69706710T2 (en) INHIBITATION OF NEOPLASTIC CELL GROWTH PRODUCED BY SUBMUCOSAL TISSUE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: COMMUNICATION PURSUANT TO RULE 85A(1)EPC

122 Ep: pct application non-entry in european phase